These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 9622240)

  • 1. Dopamine turnover and metabolism in the striatum of parkinsonian rats grafted with genetically-modified human astrocytes.
    Fitoussi N; Sotnik-Barkai I; Tornatore C; Herzberg U; Yadid G
    Neuroscience; 1998 Jul; 85(2):405-13. PubMed ID: 9622240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of aromatic L-amino acid decarboxylase for dopamine replacement by genetically modified fibroblasts in a rat model of Parkinson's disease.
    Wachtel SR; Bencsics C; Kang UJ
    J Neurochem; 1997 Nov; 69(5):2055-63. PubMed ID: 9349551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of tyrosine hydroxylase in an immortalized human fetal astrocyte cell line; in vitro characterization and engraftment into the rodent striatum.
    Tornatore C; Baker-Cairns B; Yadid G; Hamilton R; Meyers K; Atwood W; Cummins A; Tanner V; Major E
    Cell Transplant; 1996; 5(2):145-63. PubMed ID: 8689028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease.
    Shen Y; Muramatsu SI; Ikeguchi K; Fujimoto KI; Fan DS; Ogawa M; Mizukami H; Urabe M; Kume A; Nagatsu I; Urano F; Suzuki T; Ichinose H; Nagatsu T; Monahan J; Nakano I; Ozawa K
    Hum Gene Ther; 2000 Jul; 11(11):1509-19. PubMed ID: 10945765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coexpression of tyrosine hydroxylase, GTP cyclohydrolase I, aromatic amino acid decarboxylase, and vesicular monoamine transporter 2 from a helper virus-free herpes simplex virus type 1 vector supports high-level, long-term biochemical and behavioral correction of a rat model of Parkinson's disease.
    Sun M; Kong L; Wang X; Holmes C; Gao Q; Zhang GR; Pfeilschifter J; Goldstein DS; Geller AI
    Hum Gene Ther; 2004 Dec; 15(12):1177-96. PubMed ID: 15684695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long term gene therapy of Parkinson's disease using immortalized rat glial cell line with tyrosine hydroxylase gene.
    Zhuo M; Xu DH; Cao L; Xu LF; Yu FR; Zheng ZC; Liu XY
    Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Dec; 35(12):1066-71. PubMed ID: 14673496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A site-specific mutation of tyrosine hydroxylase reduces feedback inhibition by dopamine in genetically modified cells grafted in parkinsonian rats.
    Chang JW; Lee WY; Milstien S; Kang UJ
    J Neurochem; 2002 Oct; 83(1):141-9. PubMed ID: 12358737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease.
    Mandel RJ; Rendahl KG; Spratt SK; Snyder RO; Cohen LK; Leff SE
    J Neurosci; 1998 Jun; 18(11):4271-84. PubMed ID: 9592104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosine hydroxylase cells appearing in the mouse striatum after dopamine denervation are likely to be projection neurones regulated by L-DOPA.
    Darmopil S; Muñetón-Gómez VC; de Ceballos ML; Bernson M; Moratalla R
    Eur J Neurosci; 2008 Feb; 27(3):580-92. PubMed ID: 18279311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ability of grafted human sympathetic neurons to synthesize and store dopamine: a potential mechanism for the clinical effect of sympathetic neuron autografts in patients with Parkinson's disease.
    Nakao N; Shintani-Mizushima A; Kakishita K; Itakura T
    Exp Neurol; 2004 Jul; 188(1):65-73. PubMed ID: 15191803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo L-DOPA production by genetically modified primary rat fibroblast or 9L gliosarcoma cell grafts via coexpression of GTPcyclohydrolase I with tyrosine hydroxylase.
    Leff SE; Rendahl KG; Spratt SK; Kang UJ; Mandel RJ
    Exp Neurol; 1998 Jun; 151(2):249-64. PubMed ID: 9628761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of DOPA-producing astrocytes by retroviral transduction of the human tyrosine hydroxylase gene: in vitro characterization and in vivo effects in the rat Parkinson model.
    Lundberg C; Horellou P; Mallet J; Björklund A
    Exp Neurol; 1996 May; 139(1):39-53. PubMed ID: 8635567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Partial recovery of dopaminergic pathway after graft of adult mesenchymal stem cells in a rat model of Parkinson's disease.
    Bouchez G; Sensebé L; Vourc'h P; Garreau L; Bodard S; Rico A; Guilloteau D; Charbord P; Besnard JC; Chalon S
    Neurochem Int; 2008 Jun; 52(7):1332-42. PubMed ID: 18372079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopaminergic transplants suppress L-DOPA-induced Fos expression in the dopamine-depleted striatum in a rat model of Parkinson's disease.
    Ishida Y; Kuwahara I; Todaka K; Hashiguchi H; Nishimori T; Mitsuyama Y
    Brain Res; 1996 Jul; 727(1-2):205-11. PubMed ID: 8842399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term behavioral recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase.
    During MJ; Naegele JR; O'Malley KL; Geller AI
    Science; 1994 Nov; 266(5189):1399-403. PubMed ID: 7669103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic effects of astrocytes expressing both tyrosine hydroxylase and brain-derived neurotrophic factor on a rat model of Parkinson's disease.
    Wang ZH; Ji Y; Shan W; Zeng B; Raksadawan N; Pastores GM; Wisniewski T; Kolodny EH
    Neuroscience; 2002; 113(3):629-40. PubMed ID: 12150782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with L-DOPA.
    Dominguez-Meijide A; Villar-Cheda B; Garrido-Gil P; Sierrra-Paredes G; Guerra MJ; Labandeira-Garcia JL
    Neuropharmacology; 2014 Jan; 76 Pt A():156-68. PubMed ID: 23973568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implantation of encapsulated catecholamine and GDNF-producing cells in rats with unilateral dopamine depletions and parkinsonian symptoms.
    Lindner MD; Winn SR; Baetge EE; Hammang JP; Gentile FT; Doherty E; McDermott PE; Frydel B; Ullman MD; Schallert T
    Exp Neurol; 1995 Mar; 132(1):62-76. PubMed ID: 7720827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The changes of striatal dopamine levels in the brain in rat models for Parkinson's disease after gene therapy].
    Tong H; Zhang J; Xu Q
    Zhonghua Yi Xue Za Zhi; 1996 Jul; 76(7):490-2. PubMed ID: 9275495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expression and assessment of double genes of tyrosine hydroxylase gene and aromatic L-amino acid decarboxylase gene in vitro].
    Su Y; Duan CL; Zhao CL; Zhao HY; Xu QY; Yang H
    Sheng Li Xue Bao; 2003 Oct; 55(5):583-8. PubMed ID: 14566408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.